Lataa...
As a potential treatment of COVID-19: Montelukast
It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.
Tallennettuna:
| Julkaisussa: | Med Hypotheses |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Elsevier Ltd.
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7211747/ https://ncbi.nlm.nih.gov/pubmed/32416408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mehy.2020.109828 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|